Loading...
ROCO
4728
Market cap639mUSD
Jul 09, Last price  
377.00TWD
1D
-2.46%
1Q
-1.95%
Jan 2017
793.36%
IPO
1,042.42%
Name

Sunmax Biotechnology Co Ltd

Chart & Performance

D1W1MN
ROCO:4728 chart
P/E
28.29
P/S
10.13
EPS
13.33
Div Yield, %
3.08%
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
18.81%
Revenues
2.03b
+11.45%
594,145,000855,851,0001,035,659,0001,400,074,0001,688,987,0001,818,018,0002,026,164,000
Net income
726m
+6.82%
100,447,000238,077,000245,642,000533,832,000625,708,000679,405,000725,749,000
CFO
826m
+107.85%
0386,972,000243,283,000644,568,000848,556,000397,366,000825,918,000
Dividend
Aug 04, 202511.6 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in Tainan City, Taiwan, in 2001, Sunmax Biotechnology Co., Ltd. functions as a biomedical enterprise. The company specializes in the development, manufacturing, and commercialization of collagen-based medical devices across Taiwan and mainland China. Its diverse product line encompasses Porcogen, a sterile, purified collagen solution valuable for medical device applications, tissue engineering, and research. Sunmax also supplies various dermal fillers, including the Sunmax collagen implant series (I-Plus, I) and FACIALGAIN collagen implants (with and without lidocaine), engineered for correcting facial aesthetic concerns such as wrinkles. For dental procedures, they provide specialized collagen-based solutions like Sunmax collagen dental bone grafts, membranes, and granules, used for augmenting or reconstructing the alveolar ridge, extraction sockets, and in periodontics. Additionally, the Sunmax collagen bone graft matrix serves as a bone void filler that naturally resorbs and facilitates new bone formation during recovery. The company's offerings extend to skincare products, such as Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and a general collagen skincare line, all designed for post-dermal filler treatment aftercare.
IPO date
Jan 25, 2010
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT